AMP Capital Investors Ltd raised its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 9.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 96,886 shares of the biopharmaceutical company’s stock after acquiring an additional 8,525 shares during the period. AMP Capital Investors Ltd’s holdings in Alexion Pharmaceuticals were worth $11,588,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently made changes to their positions in ALXN. Andra AP fonden boosted its stake in Alexion Pharmaceuticals by 12.5% in the third quarter. Andra AP fonden now owns 9,000 shares of the biopharmaceutical company’s stock valued at $1,263,000 after acquiring an additional 1,000 shares in the last quarter. Dupont Capital Management Corp acquired a new stake in Alexion Pharmaceuticals in the third quarter valued at approximately $156,000. Chicago Equity Partners LLC acquired a new stake in Alexion Pharmaceuticals in the third quarter valued at approximately $320,000. Toronto Dominion Bank lifted its stake in shares of Alexion Pharmaceuticals by 11.4% during the third quarter. Toronto Dominion Bank now owns 84,717 shares of the biopharmaceutical company’s stock worth $11,883,000 after buying an additional 8,646 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. lifted its stake in shares of Alexion Pharmaceuticals by 793.1% during the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 77,226 shares of the biopharmaceutical company’s stock worth $10,834,000 after buying an additional 68,579 shares during the period. Institutional investors own 95.38% of the company’s stock.
In other Alexion Pharmaceuticals news, SVP Heidi L. Wagner sold 698 shares of Alexion Pharmaceuticals stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $119.35, for a total value of $83,306.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Ludwig Hantson sold 2,553 shares of Alexion Pharmaceuticals stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total transaction of $310,521.39. Following the completion of the transaction, the chief executive officer now directly owns 36,172 shares of the company’s stock, valued at approximately $4,399,600.36. The disclosure for this sale can be found here. Insiders have sold 31,253 shares of company stock valued at $3,656,229 over the last 90 days. 4.35% of the stock is currently owned by insiders.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.39. The company had revenue of $909.70 million during the quarter, compared to the consensus estimate of $880.38 million. Alexion Pharmaceuticals had a net margin of 8.36% and a return on equity of 3.42%. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.26 earnings per share. equities analysts anticipate that Alexion Pharmaceuticals, Inc. will post 6.12 EPS for the current fiscal year.
Several equities research analysts have recently commented on the stock. Cowen reiterated a “buy” rating and set a $163.00 price objective on shares of Alexion Pharmaceuticals in a research note on Friday, March 9th. ValuEngine downgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, March 1st. Zacks Investment Research downgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, February 14th. SunTrust Banks set a $172.00 price objective on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, February 12th. Finally, BMO Capital Markets lifted their price objective on shares of Alexion Pharmaceuticals from $177.00 to $180.00 and gave the stock an “outperform” rating in a research note on Friday, February 9th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and twenty have assigned a buy rating to the company’s stock. Alexion Pharmaceuticals currently has an average rating of “Buy” and an average price target of $154.64.
TRADEMARK VIOLATION WARNING: This piece was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/03/14/alexion-pharmaceuticals-inc-alxn-holdings-raised-by-amp-capital-investors-ltd.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.